Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy

Marta Muzio(IRCCS Ospedale San Raffaele), Paolo Ghia(Vita-Salute San Raffaele University), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Michela Frenquelli(Vita-Salute San Raffaele University), Cristina Scielzo(Vita-Salute San Raffaele University), Irene Vandoni(Vita-Salute San Raffaele University), Federico Caligaris‐Cappio(Vita-Salute San Raffaele University), Benedetta Apollonio(San Raffaele University of Rome)
Blood
February 22, 2008
10.1182/blood-2007-09-111344
Cited by 228

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex
|Cell|1996|3.1k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k